Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
Financial 15 Split Corp. Completes Overnight Offering of $79,109,100
-
Neptune announces appointments for its Cannabis Business
-
Intra-Cellular Therapies (ITCI) Prices 9.68M Share Common Offering at $15.50/Sh
-
DexCom (DXCM) PT Lowered to $69 at Canaccord Genuity
-
Intra-Cellular Therapies Prices $150 Million Public Offering of Common Stock
-
Pre-Open Stock Movers 09/27: (MARK) (CASC) (TWLO) Higher; (KRNT) (WLKP) (ITCI) Lower (more...)
-
UPDATE: Canaccord Genuity Upgrades Michael Kors (KORS) to Buy
-
Nike (NKE) PT Lowered to $50 at Canaccord Genuity, Negatively Revises EPS Estimates
-
Life & Banc Split Corp. Announces Successful Overnight Offering
-
Canaccord Genuity Downgrades Rio Tinto (RIO) to Hold
-
Versar, Inc. Announces Agreement and Plan of Merger with Kingswood Capital Management Affiliates
-
Canaccord Genuity Upgrades STAAR Surgical (STAA) to Buy
-
Cubic (CUB) PT Raised to $55 at Canaccord Genuity
-
The Green Organic Dutchman Announces the Hiring of New CFO and Vice President of Horticulture
-
lululemon athletica (LULU): Denim Wave Could Sink The Premium On Yoga Pants - Canaccord
-
Versartis (VSAR) PT Lowered to $9 at Canaccord Genuity
-
MongoDB, Inc. Files Registration Statement for Proposed Initial Public Offering
-
MongoDB (MDB) Files $100M IPO
-
TR1 Holding(s) in Company 2017 (7)
-
Canaccord Genuity Starts GeoPark (GPRK) at Buy
-
ROTH Capital Partners Announces the Addition of Jotin Marango, M.D., Ph.D. and Yasmeen Rahimi, Ph.D. to its Healthcare Research Team
-
TiGenix NV (TIG) PT Raised to $30 at Canaccord Genuity; Reiterates Buy
-
Blueprint Medicines (BPMC): Raising Estimates After Harvard KOL Discussion - Canaccord
-
Osisko Metals Announces Closing of $8 Million "Bought Deal" Financing of Flow-Through Shares
-
Adobe (ADBE) PT Raised to $170 at Canaccord Genuity, Hopes Selloff Offers A Better Entry
-
Quidel Corp. (QDEL) PT Raised to $48 at Canaccord Genuity, 'Revised Amendment Materially Sweetens The Deal'
-
Canaccord Genuity Downgrades Itron (ITRI) to Hold Following Acquisition
-
Canaccord Genuity Upgrades Klondex Mines (KLDX) to Buy, Rewards Largely Outweight Risks
-
Nike (NKE): A Guide Down May Be Coming - Cannacord
-
Ore Sorting Increases Grade of a Bulk Sample by 55% at Dalradian's Curraghinalt Project
-
Summit Therapeutics Announces Exercise of Underwriters’ Over-Allotment Option
-
Shorts Pile on Casual Dining Stocks - Canaccord Genuity
-
T2 Biosystems (TTOO) Prices 4.38M Common Stock Offering at $4/Share
-
T2 Biosystems Announces Pricing of Public Offering of Common Stock
-
Wall Street hits record highs, S&P 500 pierces 2,500
-
Oracle (ORCL) PT Raised to $57 at Canaccord Genuity
-
T2 Biosystems (TTOO) Plans Offering of Common Stock
-
T2 Biosystems Announces Proposed Public Offering of Common Stock
-
Eclipse Residential Mortgage Investment Corporation Announces Results of Treasury Offering
-
Financial 15 Split Corp. Announces Successful Overnight Offering
-
Summit Therapeutics plc (SMMT) Prices 1.46M ADS Offering at $12/Sh
-
Blue Apron (APRN) Headwinds Are Temporary - Canaccord
-
Summit Therapeutics Announces Pricing of Public Offering of 1,459,000 American Depositary Shares
-
Summit Therapeutics (SMMT) Announces Offering of $15M of ADSs
-
Summit Therapeutics Announces Proposed Public Offering of $15.0 Million of American Depositary Shares
-
Financial 15 Split Corp. Announces Overnight Offering
-
Iphone X shipping delay may dampen Apple's holiday quarter
-
Pre-Open Stock Movers 09/13: (SNAK) (ALDX) (JWN) Higher; (DCTH) (AMRK) (WDC) Lower (more...)
-
Tactile Systems Technology, Inc. (TCMD) Prices 3.3M Secondary at $33/Sh
-
Tactile Systems Technology (TCMD) Prices 3.3M Secondary Common Stock Offering at $33/Share

